¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06
±³À°ÀÏÀÚ : 2024-07-06
±³À°Àå¼Ò : ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç

±³À°ÁÖÁ¦ : 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¹®¸Æ¾ÐÇ×ÁøÁõ ¿¬±¸È¸

´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051

À̸ÞÀÏ : kasl@kams.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 10,000¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 13:30~13:45 Basic research in portal hypertension ÇÑ¿ëÇö(°­¿øÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 13:45~14:00 Clinical research in portal hypertension ±èÁ¤Èñ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 14:00~14:25 Antioxidative Hyaluronic Acid-Bilirubin Nanomedicine Targeting Activated Hepatic Stellate Cells for Anto-Hepatic-Fibrosis Therapy ÀÌ¿ëÇö(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 14:25~14:50 Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2 Àӽ¼ø(°è¸íÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 15:05~15:30 MASLD and MetALD increase the risk of developing hepatocellular carcinoma and incident or decompensated cirrhosis: a Korean nationwide study Á¤¼®¼Û(Â÷ÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 15:30~15:55 Impact of systemic inflammation on ACLF ¼Ûµµ¼±(°¡Å縯ÀÇ´ë)

Åä·Ð 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 15:55~16:05 Panel discussion ÀÌÇö¿õ ±èÁ¤ÇÑ(¿¬¼¼ÀÇ´ë °Ç±¹ÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 16:05~16:30 High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study À±ÁؽÄ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 16:30~16:55 Interventional procedures and research in protal hypertersion Çöµ¿È£(¼­¿ïÀÇ´ë)

Åä·Ð 07¿ù 06ÀÏ ¼øõÇâ´ëÇб³ ¼­¿ïº´¿ø µ¿Àº ´ë°­´ç 16:55~17:05 Panel discussion ¹ÚÁ¤±æ Á¤½Â¿ø(¿µ³²ÀÇ´ë ¼øõÇâÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-07-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ±¤ÁÖÀü³²³»°úÀÇ»çȸ Á¦6ȸ ÃÊÀ½ÆÄ ÇÚÁî¿Â ¿öÅ©¼ó : 2024-07-06
´ÙÀ½±Û 2024³â ´ëÇѳ»°úÇÐȸ °­¿øÁöȸ ÇÏ°è ¿¬¼ö°­Á : 2024-07-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20943 °­¿ø ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á ¹× º¸Çè½É»çÀ̽´¿¡ ´ëÇÑ ÃÖ½ÅÁö°ß : 2024-06-17 0 8 2024-06-14
20942 ¼­¿ï 2024³â ´ëÇÑ¿©¼º¼ºÀÇÇÐȸ Á¦17ȸ Ãá°èÇмú´ëȸ : 2024-06-16 0 5 2024-06-14
20941 ¼­¿ï Á¦28ȸ ¼­¿ï½Ã³»°úÀÇ»çȸ Á¤±âÃÑȸ ¹× Çмú´ëȸ : 2024-06-16 0 6 2024-06-14
20940 ´ë±¸ Á¦22Â÷ ´ë°æÇǺÎÄ¡·áÇмú´ëȸ : 2024-06-16 0 20 2024-06-14
20939 ¼­¿ï ´ëÇѼҾÆÀÀ±ÞÀÇÇÐȸ (¿Â¶óÀÎ) Á¦ 5ȸ ¼Ò¾Æ ÁøÁ¤ ±âº» ¿öÅ©¼ó : 2024-06-16 0 18 2024-06-14
20938 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø Cervical Cancer Screening and Colposcopy Educational Course: General Course : 2024-06-16 0 6 2024-06-14
20937 ÀÎõ ÀÎõ±¤¿ª½ÃÀÇ»çȸ 2024 Á¾ÇÕÇмú´ëȸ : 2024-06-16 0 4 2024-06-14
20936 ¼­¿ï (¿Â¶óÀÎ) 2024³â 2ºÐ±â °Ëü°Ë»çÁú°¡»ê¼ö°¡ Àü¹®Àη¿µ¿ª ½Å±Ô±³À°_¹«Æò : 2024-06-16 0 5 2024-06-14
20935 ´ë±¸ 2024³â Á¦3ȸ ´ë±¸°æºÏ³ëÀÎÀÇÇÐȸ ¿¬¼ö°­Á : 2024-06-16 0 5 2024-06-14
20934 ´ë±¸ Á¦24Â÷ ´ëÇѼҾƽÉÀåÇÐȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 17 2024-06-14
20933 ÀÎõ 2024³â ´ëÇѵΰæºÎÁ¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 13 2024-06-14
20932 ¼­¿ï ´ëÇѽɺÎÀüÇÐȸ 2024 ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-15 0 7 2024-06-14
20931 Á¦ÁÖ ´ëÇѸðüžÆÀÇÇÐȸ Á¦30Â÷ Çмú´ëȸ : 2024-06-15 0 5 2024-06-14
20930 Á¦ÁÖ È£³²½½°üÀý¿¬±¸È¸ Á¦76Â÷ Áý´ãȸ : 2024-06-15 0 5 2024-06-14
20929 ¼­¿ï VESC 2024 Ç÷°ü¿Ü°ú Ç÷°ü½Ã¼ú ÄÁÆÛ·±½º (Vascular Endovascular Surgery Conference) : 2024-06-15 0 5 2024-06-14
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷